SCHEDULE: Vanguard Group Reports Zero Myriad Genetics Stake

The Vanguard Group has reported a 0% beneficial ownership in Myriad Genetics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 14 to Schedule 13G for Myriad Genetics Inc.
• The filing indicates that The Vanguard Group now beneficially owns 0.00 shares of Myriad Genetics Inc. Common Stock, representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. itself no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development for Myriad Genetics. While the change is due to Vanguard's internal restructuring, the optics of a major institutional investor reporting zero ownership could create short-term market uncertainty and negative sentiment.

Negatives

• The apparent complete divestment (or disaggregation of reporting) by a major institutional investor like The Vanguard Group could be perceived negatively by the market, potentially signaling reduced institutional interest or support for Myriad Genetics Inc.

Risks

• Potential for negative market perception and investor sentiment due to the reported 0% beneficial ownership by a prominent institutional investor, even if it's an internal reporting change.
• Possible impact on the stock's liquidity or institutional ownership profile if other investors interpret this as a lack of confidence, despite the stated reason being an internal realignment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Myriad Genetics Inc.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that while this filing primarily reflects an internal reporting change within The Vanguard Group, the market might interpret a major institutional investor reporting 0% ownership as a negative signal for Myriad Genetics. This could potentially impact investor sentiment and the company's institutional ownership profile, even if Myriad's fundamentals remain unchanged.

Stakeholder Impact

• Shareholders: May experience short-term negative sentiment or price volatility due to the perceived withdrawal of a major institutional investor, even if the underlying reason is administrative.
• Investment Professionals: Will need to understand the nuances of Vanguard's internal realignment to accurately assess the implications for Myriad Genetics' stock.

Key Dates

Recommendation

The change in beneficial ownership to 0% by The Vanguard Group is attributed to an internal reporting realignment rather than a direct investment decision against Myriad Genetics' fundamentals. While this administrative change might cause short-term market uncertainty or negative sentiment, it does not inherently reflect a deterioration in Myriad Genetics' business outlook. Investors should hold and monitor for any further institutional ownership changes or company-specific news.

Keywords

Myriad Genetics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, MYGN, SEC Filing, Investment Management, Corporate Realignment